0000000000551462

AUTHOR

Patricia Flores

showing 2 related works from this author

Principales aportes de la perspectiva de género para el estudio social y reflexivo de la ciencia, la tecnología y la innovación

2019

espanolEste articulo tiene como objetivo trazar un recorrido de los principales aportes de la perspectiva de genero para la comprension de la ciencia, la tecnologia y la innovacion (CTI). La inclusion de esta perspectiva dentro del campo CTS acontecida en las ultimas decadas, ha enriquecido la comprension de las multiples relaciones que se entraman entre el dispositivo ciencia-tecnologia-innovacion y las subjetividades contemporaneas. El proposito de esta presentacion es acercar al campo disciplinar del Diseno un modo de analisis que permitiria avanzar en estudios reflexivos, en tanto proceso epistemologico fundamental, sobre las dinamicas de produccion, difusion y uso de conocimientos proy…

Complementary and alternative medicinePharmaceutical SciencePharmacology (medical)Cuadernos del Centro de Estudios de Diseño y Comunicación
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct